Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.

Bojko A, Ostasz R, Białecka M, Klimowicz A, Malinowski D, Budawski R, Bojko P, Droździk M, Kurzawski M.

Hum Immunol. 2018 Apr;79(4):213-217. doi: 10.1016/j.humimm.2018.02.003. Epub 2018 Feb 15.

PMID:
29454820
2.

Nivolumab in HIV-related non-small-cell lung cancer.

Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P.

Ann Oncol. 2017 Nov 1;28(11):2890. doi: 10.1093/annonc/mdx321. No abstract available.

PMID:
29106466
3.

Consultation Program for Patients with Cancer-Related Fatigue: A Systematic Evaluation of the Experiences of the Bavarian Cancer Society.

Fischer I, Riedner C, Bojko P, Heim ME, Rüffer JU, Besseler M, Heußner P, Milani V, Rinas N, Schlimok G, Schneider E, Koller M.

Oncol Res Treat. 2016;39(10):646-651. Epub 2016 Aug 31. No abstract available.

4.

IL17A and IL17F Gene Polymorphism Association with Psoriasis Risk and Response to Treatment in a Polish Population.

Białecka M, Ostasz R, Kurzawski M, Klimowicz A, Fabiańczyk H, Bojko P, Dziedziejko V, Safranow K, Machoy-Mokrzyńska A, Droździk M.

Dermatology. 2016;232(5):592-596. doi: 10.1159/000448090. Epub 2016 Sep 3.

5.

IL6 -174G>C polymorphism is associated with an increased risk of psoriasis but not response to treatment.

Białecka M, Ostasz R, Kurzawski M, Klimowicz A, Fabiańczyk H, Bojko P, Dziedziejko V, Safranow K, Droździk M.

Exp Dermatol. 2015 Feb;24(2):146-7. doi: 10.1111/exd.12577.

PMID:
25357087
6.

Metronomic oral cyclophosphamide in patients with advanced solid tumors.

Bojko P, Schimmel G, Bosse D, Abenhardt W.

Onkologie. 2012;35(1-2):35-8. doi: 10.1159/000336144. Epub 2012 Jan 20.

PMID:
22310343
7.

Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.

Bojko P, Abenhardt W, Schnittger S, Haferlach T.

Onkologie. 2009 Apr;32(4):191-5. doi: 10.1159/000203332. Epub 2009 Mar 13.

PMID:
19372714
8.

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.

Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T.

Haematologica. 2009 Jan;94(1):141-4. doi: 10.3324/haematol.13224. Epub 2008 Nov 23. No abstract available.

9.

[Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists].

Abenhardt W, Bosse D, Böning L, Bojko P, Hitz H, Völkl S, Fromm M, Mittermüller J, Göldel N, Schick HD, Dietzfelbinger H, Hinke A.

Dtsch Med Wochenschr. 2006 Dec 1;131(48):2707-12. German.

PMID:
17123235
10.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR.

Eur J Haematol. 2005 Jan;74(1):40-6.

PMID:
15613105
11.

Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Hüttmann A, Schirsafi K, Seeber S, Bojko P.

J Cancer Res Clin Oncol. 2005 Mar;131(3):152-6. Epub 2004 Dec 3.

PMID:
15583936
12.

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.

Müller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S, Moritz T.

Ann Hematol. 2005 Feb;84(2):110-4. Epub 2004 Sep 1.

PMID:
15340761
13.

High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer.

Bojko P, Welt A, Schleucher R, Borquez D, Scheulen ME, Vanhoefer U, Poettgen C, Stuschke M, Broelsch CE, Stamatis G, Wilke H, Seeber S, Harstrick A.

Bone Marrow Transplant. 2004 Oct;34(7):637-43.

PMID:
15300229
14.
15.

Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.

Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S.

Ann Oncol. 2003;14 Suppl 1:i29-36.

PMID:
12736228
16.

Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.

Bojko P, Hilger RA, Ruehm SG, Dirsch O, Seeber S, Scheulen ME.

Bone Marrow Transplant. 2003 Mar;31(6):487-91.

PMID:
12665845
17.

Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.

Bauer S, Hagen V, Pielken HJ, Bojko P, Seeber S, Schütte J.

Anticancer Drugs. 2002 Sep;13(8):847-9.

PMID:
12394270
19.

Analysis of commercial CD34 control samples for quality assurance.

Bojko P, Stellberg W, Mansmann V, Seeber S.

Clin Lab. 2002;48(3-4):117-24.

PMID:
11934212
20.
21.
22.

High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer.

Bojko P, Scheulen ME, Hilger R, Oberhoff C, Schindler AE, Seeber S.

J Cancer Res Clin Oncol. 2001 Apr;127(4):243-50.

PMID:
11315259
23.

Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.

Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhäuser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko P, Wolf HH, Schindler AE, Seeber S.

Clin Cancer Res. 2000 Nov;6(11):4209-16.

24.

Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells.

Bojko P, Nowak N, Moritz T, Flasshove M, Harstrick A, Seeber S.

J Clin Apher. 1999;14(2):57-62.

PMID:
10440940
25.

Kinetic study of CD34+ cells during peripheral blood stem cell collections.

Bojko P, Stellberg W, Küdde C, Scharifi M, Herrmann M, Mayer S, Harstrick A, Seeber S.

J Clin Apher. 1999;14(1):18-25.

PMID:
10355659
26.

Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors.

Bojko P, Hester JP, Durett AG, Maadani F, Körbling M, Champlin RE.

J Clin Apher. 1998;13(1):7-15.

PMID:
9590491
27.

Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.

Körbling M, Anderlini P, Durett A, Maadani F, Bojko P, Seong D, Giralt S, Khouri I, Andersson B, Mehra R, vanBesien K, Mirza N, Przepiorka D, Champlin R.

Bone Marrow Transplant. 1996 Dec;18(6):1073-9.

PMID:
8971375
28.

Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs.

Hester J, Bojko P, Rondon G, Champlin R.

Transfus Sci. 1996 Dec;17(4):585-90. Review.

PMID:
10168556
29.

Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.

Körbling M, Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R.

Bone Marrow Transplant. 1996 Nov;18(5):885-90.

PMID:
8932841
30.

Supplemental Content

Support Center